CN107188970A - 具有因子vii活性的融合蛋白质 - Google Patents

具有因子vii活性的融合蛋白质 Download PDF

Info

Publication number
CN107188970A
CN107188970A CN201710403215.1A CN201710403215A CN107188970A CN 107188970 A CN107188970 A CN 107188970A CN 201710403215 A CN201710403215 A CN 201710403215A CN 107188970 A CN107188970 A CN 107188970A
Authority
CN
China
Prior art keywords
fvii
fusion protein
linker
seq
transferrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710403215.1A
Other languages
English (en)
Chinese (zh)
Inventor
宋寅瑛
金薰泽
李峰镛
朴万勋
李镐顺
林允挺
李智慧
孙瑞延
金蚊善
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tiumbio Co ltd
Original Assignee
Tiumbio Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tiumbio Co ltd filed Critical Tiumbio Co ltd
Publication of CN107188970A publication Critical patent/CN107188970A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201710403215.1A 2010-06-04 2011-06-07 具有因子vii活性的融合蛋白质 Pending CN107188970A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2010-0052719 2010-06-04
KR20100052719 2010-06-04
CN2011800277076A CN103068854A (zh) 2010-06-04 2011-06-07 具有因子vii活性的融合蛋白质

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011800277076A Division CN103068854A (zh) 2010-06-04 2011-06-07 具有因子vii活性的融合蛋白质

Publications (1)

Publication Number Publication Date
CN107188970A true CN107188970A (zh) 2017-09-22

Family

ID=45067214

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710403215.1A Pending CN107188970A (zh) 2010-06-04 2011-06-07 具有因子vii活性的融合蛋白质
CN2011800277076A Pending CN103068854A (zh) 2010-06-04 2011-06-07 具有因子vii活性的融合蛋白质

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011800277076A Pending CN103068854A (zh) 2010-06-04 2011-06-07 具有因子vii活性的融合蛋白质

Country Status (13)

Country Link
US (2) US9644197B2 (https=)
EP (1) EP2576625B1 (https=)
JP (2) JP6143297B2 (https=)
KR (1) KR101331101B1 (https=)
CN (2) CN107188970A (https=)
AU (1) AU2011262494B2 (https=)
BR (1) BR112012030941A2 (https=)
CA (1) CA2801223C (https=)
ES (1) ES2676874T3 (https=)
MX (1) MX348567B (https=)
RU (1) RU2585231C2 (https=)
WO (1) WO2011152694A2 (https=)
ZA (1) ZA201300066B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020259109A1 (zh) * 2019-06-24 2020-12-30 王跃驹 植物生产的epo与转铁蛋白的融合蛋白及其应用
WO2020259111A1 (zh) * 2019-06-24 2020-12-30 王跃驹 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107188970A (zh) 2010-06-04 2017-09-22 株式会社蒂奥姆生物 具有因子vii活性的融合蛋白质
PT2621515T (pt) * 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
EP2960248A4 (en) * 2013-02-25 2016-08-24 Sk Chemicals Co Ltd METHOD OF ISOLATING AND CLEANING A FUSION PROTEIN WITH FACTOR VII
KR102058864B1 (ko) 2013-12-16 2019-12-24 주식회사 티움바이오 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
DK3668972T3 (da) 2017-08-18 2025-01-13 Neutrolis Inc Konstruerede dnase-enzymer og anvendelse i terapi
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
IL325846A (en) 2018-10-08 2026-03-01 Neutrolis Inc Engineering deoxyribonuclease enzymes for manufacturing and medicine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101177456A (zh) * 2001-08-30 2008-05-14 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
AU2002323501C1 (en) * 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
HK1080372A1 (zh) * 2002-05-01 2006-04-28 Schering Aktiengesellschaft 作为抗凝剂的新型组织因子目标抗体
US20060130158A1 (en) 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US20070072271A1 (en) * 2004-01-07 2007-03-29 Novo Nordisk Healthcare A/G Method for the production of recombinant proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
TWI428448B (zh) * 2006-03-24 2014-03-01 Syntonix Pharmaceuticals Inc 作為第九因子（ｆａｃｔｏｒ ｉｘ）原肽處理酶之ｐｃ５
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
EP2509502A2 (en) * 2009-12-08 2012-10-17 Koninklijke Philips Electronics N.V. A method and a correction system for correcting tracer-uptake measurements
CN107188970A (zh) 2010-06-04 2017-09-22 株式会社蒂奥姆生物 具有因子vii活性的融合蛋白质

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101177456A (zh) * 2001-08-30 2008-05-14 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020259109A1 (zh) * 2019-06-24 2020-12-30 王跃驹 植物生产的epo与转铁蛋白的融合蛋白及其应用
WO2020259111A1 (zh) * 2019-06-24 2020-12-30 王跃驹 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用

Also Published As

Publication number Publication date
CN103068854A (zh) 2013-04-24
EP2576625B1 (en) 2018-04-25
AU2011262494A2 (en) 2013-08-01
RU2585231C2 (ru) 2016-05-27
ES2676874T3 (es) 2018-07-25
AU2011262494B2 (en) 2016-01-21
ZA201300066B (en) 2014-03-26
AU2011262494A1 (en) 2013-01-24
EP2576625A2 (en) 2013-04-10
BR112012030941A2 (pt) 2017-06-06
JP6422918B2 (ja) 2018-11-14
CA2801223A1 (en) 2011-12-08
WO2011152694A3 (en) 2012-04-19
MX2012013807A (es) 2012-12-17
KR101331101B1 (ko) 2013-11-19
EP2576625A4 (en) 2013-11-06
JP2013529914A (ja) 2013-07-25
JP6143297B2 (ja) 2017-06-07
US10696960B2 (en) 2020-06-30
CA2801223C (en) 2019-12-03
JP2017000144A (ja) 2017-01-05
WO2011152694A2 (en) 2011-12-08
RU2012157301A (ru) 2014-07-20
WO2011152694A8 (en) 2013-01-17
US20160194622A1 (en) 2016-07-07
US9644197B2 (en) 2017-05-09
MX348567B (es) 2017-06-20
KR20110133454A (ko) 2011-12-12
US20130236945A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
JP6422918B2 (ja) 第ｖｉｉ因子活性を有する融合タンパク質
US8828939B2 (en) Modified vitamin K dependent polypeptides
KR101273229B1 (ko) 변형된 활성화 특성을 갖는 응고 인자 ｘ 폴리펩타이드
JP4355924B2 (ja) トロンビン切断性キメラタンパク質
AU2007218266A1 (en) Coagulation factor X polypeptides with modified activation properties
JP2009533364A (ja) 治療用ポリペプチドのインビボでの回収を増大させる方法
CN103180344A (zh) 具有因子ix活性的融合蛋白
JPH11512621A (ja) トロンビン抑制剤の解毒薬としてのトロンビンムテイン
CN113646331A (zh) 单链因子viii分子
AU2020242945B2 (en) Factor IX variants and uses thereof in therapy
US20160060612A1 (en) Method of Isolating and Purifying Fusion Protein Comprising Factor VII
US20150359859A1 (en) A method of virus inactivation in composition comprising factor vii

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170922

RJ01 Rejection of invention patent application after publication